Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on May 8)
- CONMED Corporation CNMD
- Enanta Pharmaceuticals Inc ENTA
- Helius Medical Technologies Inc HSDT
- SurModics, Inc. SRDX
Down In The Dumps
(Stocks hitting 52-week lows on May 8)
- Acasti Pharma Inc ACST
- Agenus Inc AGEN (has been falling since it reported Q1 results on Monday)
- Alimera Sciences Inc ALIM
- Aralez Pharmaceuticals Inc ARLZ (reported Q1 results Tuesday and announced plans to discontinue U.S. commercial business)
- Celgene Corporation CELG
- DENTSPLY SIRONA Inc XRAY
- Regeneron Pharmaceuticals Inc REGN
- RXi Pharmaceuticals Corp RXII
- VBI Vaccines Inc VBIV
Medical/Healthcare/Biotech Conferences
- 2018 Disruptive Growth and Healthcare Conference – May 8-9, in New York City
- Deutsche Bank 43rd Annual Health Care Conference – May 8-9, at the InterContinental Boston Hotel
See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
Stocks In Focus
Opko Posts Better-than-expected results
Opko Health Inc. OPK reported a narrower-than-expected Q1 loss of 8 cents per share on above-consensus revenues of $254.9 million.
The stock rallied 6.21 percent to $3.42 in after-hours trading.
Penumbra's Beat-And-Raise Quarter
Penumbra Inc PEN swung to a profit in Q1 and reported above-consensus revenues. The company also raised FY18 revenue guidance.
The stock rallied 5.96 percent to $144 after hours.
Synthetic Biologic Posts Narrower-Than-Expected Loss
Synthetic Biologics Inc SYN reported a loss of 2 cents per share for its Q1, narrower than the loss of 5 cents expected.
The stock jumped 11.28 percent to $0.2773 in after-hours trading.
OpGen Q1 Beats Estimates
OpGen Inc OPGN reported a narrower-than-expected loss and above-consensus revenues for its Q1.
The stock gained 3.68 percent to $1.97 in after-hours trading.
Transenterix Gains On Q1 Beat
Transenterix Inc TRXC shares were up 12 percent Wednesday morning in reaction to its Q1 results that showed break-even bottom-line results and revenues of $4.8 million. Analysts, on average, estimated a loss of 7 cents per share on revenues of $3.84 million.
On The Radar
The following companies report earnings on Wednesday:
- Mylan NV MYL Q1 EPS $0.96 Misses $0.98 Estimate, Sales $2.68B Miss $2.75B Estimate
- Endocyte, Inc. ECYT
- FibroGen Inc FGEN
- Jounce Therapeutics Inc JNCE Q1 EPS $(0.40) Misses $(0.31) Estimate, Sales $11.19M Miss $15.64M Estimate
- Neos Therapeutics Inc NEOS Q1 EPS $(0.50) Misses $(0.48) Estimate, Sales $10.72M Beat $9.79M Estimate
- AcelRx Pharmaceuticals Inc ACRX
- Adaptimmune Therapeutics PLC – ADR ADAP Q3 EPS $(0.04) Beats $(0.24) Estimate, Sales $8.19M Miss $9.1M Estimate
- Arcadia Biosciences Inc RKDA
- Array Biopharma Inc ARRY
- Audentes Therapeutics Inc BOLD
- Collegium Pharmaceutical Inc COLL
- Glaukos Corp GKOS
- Horizon Pharma PLC HZNP Q1 EPS $0.03 Misses $0.07 Estimate, Sales $223.881M Miss $234.17M Estimate
- Inovio Pharmaceuticals Inc INO
- Portola Pharmaceuticals Inc PTLA
- PTC Therapeutics, Inc. PTCT
- Puma Biotechnology Inc PBYI
- Viking Therapeutics Inc VKTX
- Ophthotech Corp OPHT Q1 EPS $(0.36) Beats $(0.40) Estimate
- Novavax, Inc. NVAX
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.